Product Description
Levomepromazine is a neuroleptic agent (an antipsychotic) which is commonly used to relieve nausea and vomiting in palliative care settings. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481825/)
Mechanisms of Action: DR Antagonist,5-HT Antagonist,mAChR Antagonist,ADR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Greece | Hungary | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Tunisia | Ukraine | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|